1. Search Result
Search Result
Results for "

and Bcl-2

" in MedChemExpress (MCE) Product Catalog:

338

Inhibitors & Agonists

1

Screening Libraries

2

Biochemical Assay Reagents

12

Peptides

1

Inhibitory Antibodies

69

Natural
Products

8

Isotope-Labeled Compounds

30

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-169925

    Bcl-2 Family Cancer
    BM-962 (Compound 31) is a potent small-molecule inhibitor of Bcl-2 with an IC50 value of 4 nM (Ki=0.8 nM) and Bcl-xL with an IC50 value of 3.9 nM (Ki <1 nM). BM-962 inhibits the cell growth in H1417 and H146 cell lines with IC50 values of 9 and 13 nM, respectively. BM-962 is promising for research of cancers .
    BM-962
  • HY-135273

    Bcl2-IN-1

    Bcl-2 Family Cancer
    A-1211212 (BCL2-IN-1) is a potent Bcl-2 inhibitor. BCL2-IN-1 binds Bcl-2 with a Ki of <0.01 nM .
    A-1211212
  • HY-118874A

    Apoptosis Bcl-2 Family Cancer
    Oblimersen sodium is a BCL-2 inhibitor targeting BCL-2 RNA. Oblimersen sodium specifically binds to the first six codons of the bcl-2 mRNA sequence, resulting in degradation of bcl-2 mRNA and induces apoptosis by down-regulating expression of Bcl-2. Oblimersen sodium can be used for cancer research .
    Oblimersen sodium
  • HY-10087
    Navitoclax
    100+ Cited Publications

    ABT-263

    Bcl-2 Family Cancer
    Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM .
    Navitoclax
  • HY-161276

    Apoptosis Bcl-2 Family Cancer
    BFC1108 is a small molecule Bcl-2 functional converter. BFC1108 induces a conformational change in Bcl-2, resulting in the exposure of its BH3 domain both in vitro and in vivo. BFC1108 effectively induces apoptosis in Bcl-2 expressing cancers. .
    BFC1108
  • HY-12020
    TW-37
    2 Publications Verification

    Bcl-2 Family Cancer
    TW-37 is a potent Bcl-2 inhibitor with Ki values of 260, 290 and 1110 nM for Mcl-1, Bcl-2 and Bcl-xL, respectively.
    TW-37
  • HY-168983

    Bcl-2 Family Cancer
    Lonitoclax is a B-cell lymphoma 2 (Bcl-2) inhibitor. Lonitoclax has comparable anti-tumor efficacy to Venetoclax (HY-15531) in both B cell and myeloid malignancy models. Lonitoclax is promising for research of relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, and certain low-grade lymphomas .
    Lonitoclax
  • HY-118874

    Bcl-2 Family Apoptosis Cancer
    Oblimersen is a BCL-2 inhibitor targeting BCL-2 RNA. Oblimersen specifically binds to the first six codons of the bcl-2 mRNA sequence, resulting in degradation of bcl-2 mRNA and induces apoptosis by down-regulating expression of Bcl-2. Oblimersen can be used for cancer research .
    Oblimersen
  • HY-10087A1

    ABT-263 dihydrochloride

    Bcl-2 Family Cancer
    Navitoclax (ABT-263) dihydrochloride is an orally active Bcl-2 inhibitor that binds to various Bcl-2 family proteins, including Bcl-xL, Bcl-2, and Bcl-w, with a Ki value of less than 1 nM. Navitoclax dihydrochloride can be used in cancer research .
    Navitoclax dihydrochloride
  • HY-143873

    Bcl-2 Family Cancer
    Bcl-2-IN-5 is a BCL-2 inhibitor with IC50s of 0.12 nM, 0.14 nM and 0.22 nM for Bcl-2 wild type, Bcl-2 D103Y and Bcl-2 G101V, respectively. Bcl-2-IN-5 inhibits the cell growth with IC50 values of 0.2 nM and 0.44 nM for Bcl 2-G101V knock-in RS4; 11 and RS4; 11 cells, respectively (WO2021208963A1; Example 155) .
    Bcl-2-IN-5
  • HY-123244

    Bcl-2 Family Apoptosis Cancer
    YC137 is a potent Bcl-2 antagonist with Kis of 1.3 μM and >100 μM for Bcl-2 and Bcl-xL when assayed in Bis-Tris buffer, respectively. YC137 inhibits the binding of the Bid BH3 peptide to Bcl-2, thus disrupting an interaction essential for the antiapoptotic activity of Bcl-2. YC137 selectively induces apoptosis of Bcl-2-dependent cells. YC137 has the potential for breast cancer research .
    YC137
  • HY-10087S

    Bcl-2 Family Cancer
    Navitoclax-d8 is the deuterium labeled Navitoclax. Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM .
    Navitoclax-d8
  • HY-165537

    FGFR Apoptosis Bcl-2 Family Caspase TNF Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Siphonaxanthin is a keto-carotenoid with anti-angiogenic and anti-inflammatory activity, which is found in green algae. Siphonaxanthin upregulates the expression of death receptor 5 (DR5), induces cancer cell apoptosis, decreases the expression of Bcl-2, and activates caspase-3. Siphonaxanthin is also an inhibitor of FGFR-1. Siphonaxanthin inhibits the proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs), as well as the outgrowth of microvessels in the rat aortic ring. Siphonaxanthin is promising for research of diseases such as cancer, diabetic retinopathy, and rheumatoid arthritis .
    Siphonaxanthin
  • HY-10087R

    ABT-263 (Standard)

    Reference Standards Bcl-2 Family Cancer
    Navitoclax (Standard) is the analytical standard of Navitoclax. This product is intended for research and analytical applications. Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM .
    Navitoclax (Standard)
  • HY-131247

    Bcl-2 Family Inflammation/Immunology Cancer
    Bcl-2-IN-2 is a potent and selective Bcl-2 inhibitor with an IC50 of 0.034 nM and also inhibits Bcl-xL with an IC50 of 43 nM, showing >1000-fold selectivity for Bcl-2 over Bcl-xL .
    Bcl-2-IN-2
  • HY-149009

    Bcl-2 Family Apoptosis Cancer
    Bcl-2-IN-9 is a novel proapoptotic Bcl-2 inhibitor with IC50 value of 2.9 μM and low cytotoxic. Bcl-2-IN-9 mediates apoptosis by down-regulating expression of Bcl-2 in cancer cells and has a high selectivity against leukemia cells .
    Bcl-2-IN-9
  • HY-12011
    HA14-1
    1 Publications Verification

    Bcl-2 Family Cancer
    HA14-1 is a Bcl-2/Bcl-XL antagonist. HA14-1 binds the designated pocket on Bcl-2 with the IC50 of ≈9 μM in competing with the Bcl-2 binding of Flu-BakBH3, and inhibits its function.
    HA14-1
  • HY-149436

    CDK Cancer
    CDK2/Bcl2-IN-1 (compound 1), a saponin and a CDK-2 inhibitor (IC50=117.6 nM) with promising cytotoxicity against cancer cells. CDK2/Bcl2-IN-1 also inhibits Bcl-2, and induces apoptosis in A549 lung cancer cells .
    CDK2/Bcl2-IN-1
  • HY-W751400

    Purapuridine hydrochloride; Solancarpidine hydrochloride; Solasodin hydrochloride

    MDM-2/p53 E1/E2/E3 Enzyme Fungal Apoptosis Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Solasodine (Purapuridine) hydrochloride is a steroidal alkaloid that occurs in plants of the Solanaceae family. Solasodine hydrochloride induces apoptosis by inhibiting the p53-MDM2 complex, p21Waf1/Cip1, and Bcl-2 proteins. Solasodine hydrochloride has neuroprotective, antifungal, hypotensive, anticancer, antiatherosclerotic, antiandrogenic and anti-inflammatory activities .
    Solasodine hydrochloride
  • HY-174403

    Bcl-2 Family c-Myc Apoptosis Caspase Cancer
    c-MYC/BCL2 ligand 1 iodide is a dual-targeting c-MYC/Bcl-2 G4 ligand with Kd values of 0.90 μM (c-MYC G4) and 0.56 μM (Bcl-2 G4). c-MYC/BCL2 ligand 1 iodide inhibits c-MYC and Bcl-2 gene transcription by binding to G4-forming sequences and downregulates their protein expression. c-MYC/BCL2 ligand 1 iodide inhibits suppresses migration, induces caspase-dependent apoptosis, and triggers cell cycle G1 arrest in MCF-7 cells. c-MYC/BCL2 ligand 1 iodide significantly suppresses tumor growth in a 4T1 syngeneic model with no observable toxicity. c-MYC/BCL2 ligand 1 iodide can be used for the research of breast cancer.
    c-MYC/BCL2 ligand 1 iodide
  • HY-163309

    Bcl-2 Family Cancer
    Bcl-2-IN-19 (compound 27) is a potent Bcl-2 inhibitor for targeting breast cancer .
    Bcl-2-IN-19
  • HY-156620

    Bcl-2 Family Cancer
    Lacutoclax is a Bcl-2 inhibitor with antineoplastic activity .
    Lacutoclax
  • HY-136714

    Bcl-2 Family Cancer
    Bcl-2-IN-3 (Compound 10) is a Bcl-2 inhibitor. Bcl-2-IN-3 can be used for the research of cancer .
    Bcl-2-IN-3
  • HY-122047

    Autophagy Cancer
    SW063058 is an autophagy inducer that specifically disrupts the binding of Beclin 1 to Bcl-2 while leaving the interaction between Bcl-2 and pro-apoptotic members like Bax and BIM unaffected. By inhibiting the negative regulatory effects of Bcl-2 on Beclin 1, which is crucial for the initiation of autophagy, SW063058 promotes autophagic activity without triggering cytotoxicity, apoptosis, or other forms of cell death in vitro.
    SW063058
  • HY-149623

    Bcl-2 Family Cancer
    Bcl-2-IN-13 is a Bcl-2 inhibitor with an IC50 value of 17 nM. Bcl-2-IN-13 can be used in cancer research .
    Bcl-2-IN-13
  • HY-109617

    Bcl-2 Family Cancer
    4-(4-Fluorophenyl)benzoic acid (Compoud 6) can bind to Bcl-2 with a KD value of 400 μM. 4-(4-Fluorophenyl)benzoic acid can be used to develope Bcl-2 selective anti-cancer agent .
    4-(4-Fluorophenyl)benzoic acid
  • HY-169083

    Apoptosis Bcl-2 Family Cancer
    Bcl-2-IN-22 (compound 1) is a gold(I) NHC complex with anticancer activity. Bcl-2-IN-22 induces apoptosis via the mitochondrial pathway with an IC50 value of 0.014 μM. In addition, Bcl-2-IN-22 targets BCL-2 family members and exhibits pro-apoptosis and resensitization properties in multidrug-resistant leukemia cells that overexpress BCL-2 .
    Bcl-2-IN-22
  • HY-142209

    Bcl-2 Family Cancer
    ABBV-167 is a phosphate proagent of the BCL-2 inhibitor venetoclax.
    ABBV-167
  • HY-149622

    Bcl-2 Family Cancer
    Bcl-2-IN-12 (Compound 1) is a Bcl-2 inhibitor (IC50: 6 nM). Bcl-2-IN-12 can be used for cancer research .
    Bcl-2-IN-12
  • HY-129179
    Lisaftoclax
    1 Publications Verification

    APG-2575; Bcl-2/Bcl-xl inhibitor 1

    Bcl-2 Family Cancer
    Lisaftoclax (compound 6) is a dual Bcl-2 and Bcl-xl inhibitor with anti-tumor activity, extracted from patent WO2018027097A1. Lisaftoclax exhibits IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively .
    Lisaftoclax
  • HY-P10057

    Apoptosis Cancer
    cpm-1285 induces apoptosis by functionally blocking intracellular Bcl-2 and related death antagonists. cpm-1285 shows strong binding potency to Bcl-2 with an IC50 value of 130 nM. cpm-1285 reduces tumor burden in mice .
    cpm-1285
  • HY-161577

    Bcl-2 Family Cancer
    BFC1103 is a small-molecule compound whose primary mechanism of action involves interaction with a specific domain of Bcl-2, particularly its loop domain. This interaction induces a conformational change in Bcl-2, exposing its BH3 (Bcl-2 homology 3) domain, thereby switching Bcl-2's function from anti-apoptotic to pro-apoptotic. The cell death induced by BFC1103 is dependent on the presence of Bax or Bak, both of which are key proteins involved in the intrinsic apoptotic pathway mediated by mitochondria. BFC1103 has successfully inhibited lung metastasis of triple-negative breast cancer in mouse models. It can be utilized in studying the roles of Bcl-2 family proteins in cancer development and how they impact the survival and proliferation of cancer cells .
    BFC1103
  • HY-149624

    Bcl-2 Family Cancer
    Bcl-2-IN-14 (Compound 13c) is a BCL-2 inhibitor with an IC50 value of 0.471 μM. Bcl-2-IN-14 can be used in cancer research .
    Bcl-2-IN-14
  • HY-149625

    Bcl-2 Family Cancer
    Bcl-2-IN-15 (Compound 13d)) is a Bcl-2 inhibitor (IC50: 363 nM). Bcl-2-IN-15 inhibits the proliferation ofNCI leukemia cancer cell line .
    Bcl-2-IN-15
  • HY-N1157

    Apigenin-5-methyl ether

    Bcl-2 Family Caspase Neurological Disease
    Thevetiaflavone could upregulate the expression of Bcl-2 and downregulate that of Bax and caspase-3.
    Thevetiaflavone
  • HY-101083

    Bcl-2 Family Cancer
    BDA-366 is a potent Bcl2 antagonist (Ki = 3.3 nM), binding Bcl2-BH4 domain with high affinity and selectivity. BDA-366 induces conformational change in Bcl2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer cells .
    BDA-366
  • HY-129700

    Bcl-2 Family Cancer
    MCL-1/BCL-2-IN-2 (Compound 6) is a potent and selective Mcl-1 and Bcl-2 dual inhibitor .
    MCL-1/BCL-2-IN-2
  • HY-129702

    Bcl-2 Family Cancer
    MCL-1/BCL-2-IN-4 (Compound 7) is a potent and selective Mcl-1 and Bcl-2 dual inhibitor .
    MCL-1/BCL-2-IN-4
  • HY-160108

    Bcl-2 Family Others
    Bcl-2-IN-17 is a Bcl2 inhibitor and can be used for the research of diseases associated with Bcl anti-apoptotic protein .
    Bcl-2-IN-17
  • HY-153953

    Bcl-2 Family Cancer
    Bcl-2-IN-11 (compound 6) is a potent and selective Bcl-2 activity inhibitor, with an IC50 of 0.9 nM. Bcl-2-IN-11 shows weak inhibition of Bcl-xl (IC50 > 1000 nM). Bcl-2-IN-11 can be used for the research of a variety of cancers caused by abnormal overexpression of Bcl-2 family proteins: especially malignant hematologic diseases of acute lymphoid leukemia, etc. Bcl-2-IN-11 can also avoid toxic side effects caused by Bcl-xl inhibition, such as thrombocytopenia .
    Bcl-2-IN-11
  • HY-19551

    ApoG2

    Bcl-2 Family Apoptosis Autophagy Fungal ROS Kinase Infection Cancer
    Apogossypolone (ApoG2) is an orally active Bcl-2 family proteins inhibitor with Ki values of 35, 25 and 660 nM for Bcl-2, Mcl-1 and Bcl-XL, respectively. Apogossypolone shows antitumor activities, induces cell apoptosis and autophagy . Apogossypolone also has antifungal activity .
    Apogossypolone
  • HY-P2343

    Apoptosis Cancer
    BH3 hydrochloride, a BBB penetrated peptide, provoke apoptosis either by direct activation of pro-apoptotic Bax/Bak or by neutralizing anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-XL, Bcl-w, Mcl-1 and A-1) via their BH3 domian .
    BH3 hydrochloride
  • HY-163308

    Bcl-2 Family Cancer
    Bcl-2-IN-18 (Compound 23) is a breast cancer Bcl-2 inhibitor with a IC50 value of 4.7 μM for MCF-7. Bcl-2-IN-18 has antitumor activity .
    Bcl-2-IN-18
  • HY-161410

    PROTACs Apoptosis Bcl-2 Family Cancer
    WH244 is a second generation BCL-2 and BCL-xL dual depressant (PROTAC). The primary activity of WH244 is the specific degradation of BCL-2 and BCL-xL proteins (BCL-xL: DC50=0.6 nM, BCL-2: DC50=7.4 nM). WH244 promotes their ubiquitination and subsequent proteasome degradation by targeting these proteins, thereby restoring the cell's apoptosis pathway. WH244 has good antitumor activity. (Pink: BCL-2/BCL-xL ligand (HY-161415); Blue: E3 ligase ligand (HY-112078); Black: linker) .
    WH244
  • HY-P5327

    Bcl-2 Family Others
    r8 Bid BH3 is a biological active peptide. (The Bid BH3 is a pro-apoptotic member of the 'BH3-only' subset of BCL-2 family proteins that constitute a critical control point in apoptosis. r8BIDBH3 is lethal to human leukemia cell lines that expresse Bcl-2. The Bcl-2 antagonists may have the potential to be efficacious in cancer therapy. Poly-D-arginine (d-isomer as denoted by rrrrrrrr) is fused to the Bid BH3 peptide to facilitate cellular uptake of the peptide.)
    r8 Bid BH3
  • HY-RS01417

    Small Interfering RNA (siRNA) Bcl-2 Family Others

    BCL2 Rat Pre-designed siRNA Set A contains three designed siRNAs for BCL2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    BCL2 Rat Pre-designed siRNA Set A
    BCL2 Rat Pre-designed siRNA Set A
  • HY-RS01416

    Small Interfering RNA (siRNA) Bcl-2 Family Others

    Bcl2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bcl2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Bcl2 Mouse Pre-designed siRNA Set A
    Bcl2 Mouse Pre-designed siRNA Set A
  • HY-RS01415

    Small Interfering RNA (siRNA) Bcl-2 Family Others

    BCL2 Human Pre-designed siRNA Set A contains three designed siRNAs for BCL2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    BCL2 Human Pre-designed siRNA Set A
    BCL2 Human Pre-designed siRNA Set A
  • HY-15191
    Sabutoclax
    1 Publications Verification

    BI-97C1

    Bcl-2 Family Cancer
    Sabutoclax is a potent and effective Bcl-2 Family (Bcl-2, Bcl-XL, Mcl-1, Bfl-1) inhibitor with IC50s of 0.32 μM, 0.31 μM, 0.20 μM, and 0.62 μM, respectively. Sabutoclax increases Bax, Bim, PUMA and survivin expression .
    Sabutoclax
  • HY-162820

    Bcl-2 Family Cancer
    Bcl-2-IN-21 (compound C1) is an iridium compound with anticancer activity that targets and inhibits Bcl-2. Bcl-2-IN-21 inhibits colony formation of cancer cells and induces elevated levels of Bax and caspase 3 .
    Bcl-2-IN-21

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: